President Trump plans to impose 25% tariffs on pharmaceuticals and other sectors, aiming to bring drug manufacturing back to the US. While intended to support domestic industries, these tariffs could lead to higher drug prices and a trade war affecting both the US and EU pharmaceutical sectors. Ireland and Denmark are particularly vulnerable, with significant economic repercussions expected. The EU may retaliate with countermeasures against US pharma companies, potentially escalating tensions and impacting global pharmaceutical supply chains. Teljes cikk (Euronews.com)